ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Mace Security International, Inc.
0.0157
0.0000
成交量:
- -
成交額:
- -
市值:
104.42萬
市盈率:
-0.40
高:
0.0157
開:
0.0157
低:
0.0157
收:
0.0157
52周最高:
0.0157
52周最低:
0.0157
股本:
6,659.61萬
流通股本:
6,121.55萬
量比:
0.11
換手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
-0.0391
每股收益(LYR):
-0.0309
淨資產收益率:
-106.94%
總資產收益率:
-19.75%
市淨率:
0.51
市盈率(LYR):
-0.51
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
減肥版司美格魯肽在中國獲批新適應症,系中國首個!減重藥為啥要管這件事?
上观新闻
·
2025/12/22
未來已來,看口服司美如何重塑糖尿病的治療價值
智通财经
·
2025/12/10
告別針頭!口服司美格魯肽片實現16.6%體重減輕
医药地理
·
2025/09/25
不止減重,司美格魯肽亮出心血管獲益王牌
药时代
·
2025/09/17
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MACE"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MACE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","market":"US","secType":"STK","nameCN":"Mace Security International, Inc.","latestPrice":0.01568,"timestamp":1771621200000,"preClose":0.01568,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":61215490,"shares":66596075,"eps":-0.039075,"marketStatus":"休市中","change":0,"latestTime":"02-20 16:00:00 EST 延時","open":0.01568,"high":0.01568,"low":0.01568,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.039075,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.01568,"volumeRatio":0.10668023659160104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MACE\",,,,,undefined,":{"symbol":"MACE","floatShares":61215490,"roa":"-19.75%","roe":"-106.94%","lyrEps":-0.030906,"volumeRatio":0.10668023659160104,"shares":66596075,"dividePrice":0,"high":0.01568,"amplitude":0,"preClose":0.01568,"low":0.01568,"week52Low":0.01568,"pbRate":"0.51","psRate":"0.18","week52High":0.01568,"institutionHeld":0.0001,"latestPrice":0.01568,"eps":-0.039075,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.039075,"open":0.01568,"prevYearClose":0.01568,"prevWeekClose":0.0157,"prevMonthClose":0.0157,"prevQuarterClose":0.0157,"fiveDayClose":0.0157,"twentyDayClose":0.0157,"sixtyDayClose":0.0157},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MACE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-09","symbol":"MACE","reason":null,"defaultRemindTime":1733754600000,"announcedDate":"2024-12-06","type":"delisting","dateTimestamp":1733720400000},{"market":"US","date":"2024-09-30","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1727668800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-02","symbol":"MACE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1712030400000,"reportTimeType":"","actualEps":null},{"date":"2023-11-14","symbol":"MACE","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1699995600000,"name":null,"time":"盤後","dateTimestamp":1699938000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MACE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MACE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MACE\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593043353","title":"減肥版司美格魯肽在中國獲批新適應症,系中國首個!減重藥為啥要管這件事?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593043353","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593043353?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:56","pubTimestamp":1766411806,"startTime":"0","endTime":"0","summary":"2025年已近尾声,减重药赛道的竞争没有丝毫放松。就在今天(12月22日),司美格鲁肽注射液(商品名:诺和盈)的心血管适应症上市申请获得中国国家药品监督管理局(NMPA)批准,适用于降低已确诊为心血管疾病、且BMI≥27成人患者的主要心血管不良事件(心血管死亡、非致死性心肌梗死、非致死性卒中)的风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598584460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4183","MACE","BK4157"],"gpt_icon":0},{"id":"2590518307","title":"未來已來,看口服司美如何重塑糖尿病的治療價值","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518307?lang=zh_tw&edition=fundamental","pubTime":"2025-12-10 16:37","pubTimestamp":1765355850,"startTime":"0","endTime":"0","summary":"第二代的长效及速效胰岛素联合应用,已成为糖尿病晚期管理的核心,但可能面临低血糖和体重增加等问题。“口服化”必然成为糖尿病治疗发展的新方向。在实现治疗便利性、且保证疗效的同时,口服司美格鲁肽在心血管保护和降低肾病风险方面的表现也引发业内关注。目前,2型糖尿病患者在降糖、降低心血管疾病及肾病风险方面的综合代谢治疗获益已经成为内分泌专业医生的治疗关注重点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MACE","BK4183","BK4157"],"gpt_icon":0},{"id":"2570909606","title":"告別針頭!口服司美格魯肽片實現16.6%體重減輕","url":"https://stock-news.laohu8.com/highlight/detail?id=2570909606","media":"医药地理","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570909606?lang=zh_tw&edition=fundamental","pubTime":"2025-09-25 17:10","pubTimestamp":1758791432,"startTime":"0","endTime":"0","summary":"结果显示:在严格遵循治疗的患者中,口服司美格鲁肽片25 mg组体重降幅达16.6%,显著高于安慰剂组的2.7%;34.4%的受试者减重超过20%,而安慰剂组这一比例仅为2.9%。即使考虑部分患者用药依从性不足的情况,口服组仍实现13.6%的体重降幅,近30%的患者减重超过20%。其中,司美格鲁肽注射液表现尤为突出,单季度销售额高达8.16亿元,占据市场主导地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925182127a4433b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4157","LU1093756168.USD","BK4183","BK4585","BK4599","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","BK4007","BK4532","BK4588","MACE","NVO"],"gpt_icon":1},{"id":"2568459038","title":"不止減重,司美格魯肽亮出心血管獲益王牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2568459038","media":"药时代","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568459038?lang=zh_tw&edition=fundamental","pubTime":"2025-09-17 10:30","pubTimestamp":1758076249,"startTime":"0","endTime":"0","summary":"诺和诺德更是明确指出:诺和盈所展现的心脏保护获益是司美格鲁肽分子独有。事实上,司美格鲁肽在心血管保护方面的显著获益在机制研究阶段已有迹可循。该研究首次证实了诺和盈是全球首个在伴有确诊心血管疾病但无糖尿病的超重或肥胖成人中,显示出心血管结局获益的减重药物4。在全球范围内,每年约有2,100万人死于心血管疾病6。约有三分之二与肥胖相关的死亡与心血管疾病相关7,8。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091711560497979a96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1035773651.USD","LU0985320562.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU1057294990.SGD","LU0203347892.USD","LU1430594728.SGD","SG9999001176.SGD","LU1929549753.HKD","LU1069347547.HKD","LU2023250504.SGD","IE00BN8TJ469.HKD","BK4550","BK4599","LU2468319806.SGD","LU1116320901.HKD","BK4585","LU1571399168.USD","IE00B1BXHZ80.USD","BK4588","LU2361044949.HKD","LU2023250843.SGD","SG9999014575.USD","LU0208291251.USD","LU0122379950.USD","LU1061106388.HKD","LU1934455863.HKD","RCT","IE00BBT3K403.USD","LU1291159041.SGD","LU2089984988.USD","IE00B2B36J28.USD","IE0009355771.USD","LU1162221912.USD","LU1934455277.USD","SGXZ57979304.SGD","NVO","IE00BLSP4239.USD","LU1917777945.USD","LU1066051225.USD","LU0289739699.SGD","LU2324357040.USD","LU0965509010.AUD","MACE","LU1066053197.SGD","SG9999002232.USD","IE00BSNM7G36.USD","MRK","IE000M9KFDE8.USD","LU1585245621.USD"],"gpt_icon":1}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MACE\",params:#limit:6,delay:false,,,undefined,":[]}}